Funding rounds, M&A, IPOs, and market analysis—where capital is flowing and why the tape moves.
CMS has approved more than 150 digital health companies to participate in its ACCESS chronic care pilot, aiming to advance technology-driven care models with outcome-based payments.
CMS has approved more than 150 digital health companies to participate in its ACCESS chronic care pilot, aiming to advance technology-driven care models with outcome-based payments.
READ MORE
In the first quarter of 2026, digital health startups attracted $4 billion in funding across 110 deals, marking a rebound in investment despite ongoing market uncertainties.
March 2026 was marked by several significant funding rounds within the health technology sector. These investments reflect growing investor confidence and innovation momentum in healthcare technology.
Amazon has integrated Berry Street into its Health Benefits Connector, broadening access to insurance-covered nutrition therapy for its customers.
Health systems are broadening their evaluation of AI tools’ return on investment, increasingly factoring in benefits such as clinician burnout reduction alongside financial metrics.
Muse Capital highlights the limitations of pure direct-to-consumer healthcare models, emphasizing the need for integration with clinical and payer ecosystems.
Lantern has raised $30 million in funding to accelerate its growth focused on employers and health plans. This funding round is led by significant investors including Morgan Health and Echo Health Ventures.
Recent data from BioSpace reveals that professionals in the U.S. life sciences industry can achieve notable salary increases by changing employers, with many seeing rises of 6% or more.
Despite considerable financial resources, major pharmaceutical companies are favoring mid-cap deals, prompting suggestions for pursuing larger acquisitions to drive impactful industry change.
Breakout Ventures has raised $114 million to invest in early-stage biotech companies that leverage artificial intelligence technology, aiming to support innovation at the earliest phases of drug development.
Science Corp. successfully raised $230 million to support the development and regulatory approval process of PRIMA, its innovative wireless retinal implant, currently under FDA review.
